This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Abstract Details
Activity Number:
|
378
|
Type:
|
Invited
|
Date/Time:
|
Tuesday, August 3, 2010 : 2:00 PM to 3:50 PM
|
Sponsor:
|
International Indian Statistical Association
|
Abstract - #305922 |
Title:
|
Who Needs Bayesian Phase I Trials?
|
Author(s):
|
Rick Chappell*+
|
Companies:
|
University of Wisconsin-Madison
|
Address:
|
600 Highland Ave., K6/430, Madison, WI, 53792,
|
Keywords:
|
clinical trials ;
phase I ;
dose-escalation ;
maximum tolerated dose ;
Bayesian designs
|
Abstract:
|
This talk addresses the conduct of Phase I trials in serious illnesses for which the goal is to find the maximum tolerable dose of a other treatment or combination of treatments. Tolerability is framed with respect to the frequency of explicitly defined toxicities. That the so-called "traditional" or escalation-only 3+3 design is flawed has been noted by Storer, who proposed more useful algorithmic designs in 1989, O'Quigley, et al., who published a Bayesian alternative in 1990, and many authors since.
I will consider three aspects of phase I trials in which the Bayesian paradigm may be applied: dose selection, escalation algorithm, and final analysis. I see no choice but to be Bayesian in the first and no harm in being Bayesian for the analysis. Bayesian escalation methods are flexible but at the cost of incurring ethical and logistic difficulties which limit their application.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2010 program
|
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.